Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 2 of the last 2 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Legal situation KBO
Vrijwillige ontbinding – vereffening according to the CBE.
Financials
Financial year 2025
SAMABRIVA BIOMANUFACTURING from Liège, company number BE1002863501, closed financial year 2025 with a result of € -721,999 after tax. For that financial year SAMABRIVA BIOMANUFACTURING recorded a gross margin of € -472,631 and equity of € -933,529. Compared with financial year 2024, the result moved from € -544,541 to € -721,999. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 8, 2026.
€ -933,529
▼ € 603,723 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -721,999
▼ 33 % more loss than in 2024
Profit after tax over the fiscal year.
€ 393,450
▼ 80% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -1.3 million.
People and assets in 2025
€ 130,074
▲ 278% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 2,795
▲ 265% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 104,068
▲ 275% vs 2024
€ 5,661 is repaid this year. At this pace the long-term loan is gone in ≈ 18 years.
€ 106,541
▼ 69% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 9,809
▲ 52% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|
| Gross margin | € -448,373 | € -472,631 | ▼ € 24,258 |
| Profit after taxes | € -544,541 | € -721,999 | ▼ € 177,458 |
| Equity | € -329,806 | € -933,529 | ▼ € 603,723 |
| Total debts | € 2,630,205 | € 2,015,218 | ▼ 23% |
| Cash | € 1,954,688 | € 393,450 | ▼ 80% |
| Retained profit | € -544,541 | € -1,266,540 | ▼ € 721,999 |
| Bank debt | € 27,744 | € 104,068 | ▲ 275% |
| Balance sheet total | € 2,300,399 | € 1,081,690 | ▼ 53% |
Key figures of SAMABRIVA BIOMANUFACTURING, fiscal years 2024 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to SAMABRIVA BIOMANUFACTURING?
What happened at SAMABRIVA BIOMANUFACTURING in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
SAMABRIVA BIOMANUFACTURING is active according to the CBE. Legal situation: Vrijwillige ontbinding – vereffening.
- SAMABRIVA France SA stepped down as director. NBB
- P&L Eagle SRL stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 721,999. Source: NBB ↗
- New establishment in Liège. KBO
- SAMABRIVA France SA became a director. NBB
- P&L Eagle SRL became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 544,541 loss in 2024 to € 721,999 loss in 2025.
Paid € 316 in corporate taxes since 2024.
A new publication or filing at SAMABRIVA BIOMANUFACTURING? We notify you, reason included.
Follow SAMABRIVA BIOMANUFACTURINGDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by SAMABRIVA France.
Directors
According to the 2025 annual accounts
SAMABRIVA France SA
Director · represented by Guillet Marina
since 2023 · until 2029
since 2023 · until 2029
Shareholders
SAMABRIVA France
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Avenue Pré-Aily 14
4031 Liège
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1002.863.501
- VAT number
- BE 1002.863.501
- Registered office
- Avenue Pré-Aily 14, 4031 Liège
- Names & denominations
- SAMABRIVA BIOMANUFACTURING
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Vrijwillige ontbinding – vereffening
- Start date
- 30 November 2023
- Peppol
- Active · Active since 3 Nov 2025
- Contact
- [email protected] +33614817478
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Speur- en ontwikkelingswerk op biotechnologisch gebied
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Vervaardiging van parfums en toiletartikelen
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Vervaardiging van geneesmiddelen
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering